Response to: 'Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study' by Sanmarti et al

Affiliations

¹ Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital and Faculty of Medicine, National Yang Ming University, Taipei, Taiwan Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan Institute of Microbiology and Immunology, School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
² Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital and Faculty of Medicine, National Yang Ming University, Taipei, Taiwan Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan.

Comment

Der-Yuan Chen et al. Ann Rheum Dis. 2015 Aug.

. 2015 Aug;74(8):e43.

doi: 10.1136/annrheumdis-2015-207543. Epub 2015 Apr 3.

¹ Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital and Faculty of Medicine, National Yang Ming University, Taipei, Taiwan Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan Institute of Microbiology and Immunology, School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
² Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital and Faculty of Medicine, National Yang Ming University, Taipei, Taiwan Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan.

No abstract available

Keywords: Anti-TNF; DMARDs (biologic); Rheumatoid Arthritis.

Comment on

Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.
Chen DY, Chen YM, Tsai WC, Tseng JC, Chen YH, Hsieh CW, Hung WT, Lan JL. Chen DY, et al. Ann Rheum Dis. 2015 Mar;74(3):e16. doi: 10.1136/annrheumdis-2013-203893. Epub 2014 Jan 17. Ann Rheum Dis. 2015. PMID: 24442879
Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study.
Sanmarti R, Inciarte-Mundo J, Estrada-Alarcon P, Garcia-Manrique M, Narvaez J, Rodriguez-Moreno J, Gomez-Centeno A, Pascal M, Yagüe J. Sanmarti R, et al. Ann Rheum Dis. 2015 Aug;74(8):e42. doi: 10.1136/annrheumdis-2015-207530. Epub 2015 Mar 24. Ann Rheum Dis. 2015. PMID: 25805737 No abstract available.